No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
XBI240719C102000
- 0.89
- +0.43+93.48%
15min DelayClose Jul 16 16:00 ET
1.92High0.57Low
0.75Open0.46Pre Close2.17K Volume685 Open Interest102.00Strike Price218.72KTurnover26.57%IV1.02%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.89Extrinsic Value100Contract SizeAmericanOptions Type0.4894Delta0.1545Gamma103.93Leverage Ratio-0.1759Theta0.0044Rho50.86Eff Leverage0.0387Vega
Intraday
- 5D
- Daily
News
Top Performing Industry ETFs In June: Software Leads Returns, Chipmakers Attract Most Inflows
June closed on a high note for the stock market, with the S&P 500, tracked by the SPDR S&P 500 ETF Trust (NYSE:SPY), gaining 3.2%, despite significant disparities in sector and industry performances.T
Will Trump's Debate Advantage Give Biotech and Healthcare Stocks a Lift?
As the dust settles on the latest presidential debate, market analysts are scrutinizing the implications of a potential shift in the political landscape.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
SPDR S&P Biotech ETF Declares Quarterly Distribution of $0.1148
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
Biotech stocks are high-risk, high-return opportunities that are under the mercy of several make-or-break catalysts, most of which are binary events. It pays to remain cognizant of the timing of these
SPDR S&P Biotech ETF To Go Ex-Dividend On June 24th, 2024 With 0.11478 USD Dividend Per Share
June 21st (Eastern Time) - $SPDR S&P Biotech ETF(XBI.US)$ is trading ex-dividend on June 24th, 2024.Shareholders of record on June 24th, 2024 will receive 0.11478 USD dividend per share on June 26th,
Comments
Jinta Hong, CFA
Background
As we enter the second half of 2024, the global financial landscape remains dynamic, influenced by international relations and economic policies. While major markets like the US, Japan, India, and parts of Europe have seen significant growth, Australia has faced challenges such as inflation and weak Chinese economic performance. The $S&P/ASX 200(.XJO.AU$ index reached a historic peak in April ...
Background
As we enter the second half of 2024, the global financial landscape remains dynamic, influenced by international relations and economic policies. While major markets like the US, Japan, India, and parts of Europe have seen significant growth, Australia has faced challenges such as inflation and weak Chinese economic performance. The $S&P/ASX 200(.XJO.AU$ index reached a historic peak in April ...
+7
76
7
$Ginkgo Bioworks(DNA.US$ smth happened to this... 0.1 soon
It does not follow the XBI and Russell 2000 up trend for this period of time. Meaning market drops, it drops. Market ups, it still drop. Gonna cut off from my side
It does not follow the XBI and Russell 2000 up trend for this period of time. Meaning market drops, it drops. Market ups, it still drop. Gonna cut off from my side
5
$Merck & Co(MRK.US$ on the prowl for acquisitions up to $15 billion.
$Merck & Co(MRK.US$ already has an active partnership with $Janux Therapeutics(JANX.US$ for two TRACtr targets, and CEO Davis has evinced a preference for acquisition of $SPDR S&P Biotech ETF(XBI.US$ in which $Merck & Co(MRK.US$ already has a seat at the table.
$Merck & Co(MRK.US$ acquisition of $HARP earlier this year (for a song) shows their interest in the T Cell engag...
$Merck & Co(MRK.US$ already has an active partnership with $Janux Therapeutics(JANX.US$ for two TRACtr targets, and CEO Davis has evinced a preference for acquisition of $SPDR S&P Biotech ETF(XBI.US$ in which $Merck & Co(MRK.US$ already has a seat at the table.
$Merck & Co(MRK.US$ acquisition of $HARP earlier this year (for a song) shows their interest in the T Cell engag...
+1
9
Background and Recent Performance
$Bristol-Myers Squibb(BMY.US$ is a global biopharmaceutical company known for its innovative treatments in oncology, immunology, and cardiovascular diseases. Over the past year, BMY has faced some challenges, with its stock price nearing its 52-week low. As of June 20, 2024, the stock is trading at $40.795, which is close to its 52-week low of around $40.00.
$Bristol-Myers Squibb(BMY.US$
Despite recent performance s...
$Bristol-Myers Squibb(BMY.US$ is a global biopharmaceutical company known for its innovative treatments in oncology, immunology, and cardiovascular diseases. Over the past year, BMY has faced some challenges, with its stock price nearing its 52-week low. As of June 20, 2024, the stock is trading at $40.795, which is close to its 52-week low of around $40.00.
$Bristol-Myers Squibb(BMY.US$
Despite recent performance s...
15
Short Interest of Life Sciences Companies at a High Point.
Interesting list of name for the incoming CPI..
$Novavax(NVAX.US$ $SPDR S&P Biotech ETF(XBI.US$ $S&P 500 Index(.SPX.US$
Interesting list of name for the incoming CPI..
$Novavax(NVAX.US$ $SPDR S&P Biotech ETF(XBI.US$ $S&P 500 Index(.SPX.US$
3
Read more
151652693 : There are many theories that do not touch the QE factor that caused the rise and harvest of global finance
151336027 :
151830249 :
151078437 :
151817588 :
View more comments...